CENCORA, INC. (COR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.04%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.04% | Share-based compensation / revenue. Period ending 2026-06-30. $148.73M ÷ $332.77B × 100 ≈ 0.04% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 332.77B USD | |
| Stock-based compensation | 148.73M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 3.04B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $332.77B | $148.73M | $3.04B | (m) | (m) | 0.04% | (m) | (m) |
| 2026-03-31 | (m) | $328.68B | $143.18M | $2.79B | (m) | (m) | 0.04% | (m) | (m) |
| 2025-12-31 | (m) | $325.78B | $143.63M | $2.68B | (m) | (m) | 0.04% | (m) | (m) |
| 2025-09-30 | (m) | $321.33B | $147.96M | $2.63B | (m) | (m) | 0.05% | (m) | (m) |
| 2025-06-30 | (m) | $316.65B | $156.61M | $2.74B | (m) | (m) | 0.05% | (m) | (m) |
| 2025-03-31 | (m) | $310.23B | $155.60M | $2.54B | (m) | (m) | 0.05% | (m) | (m) |
| 2024-12-31 | (m) | $303.19B | $155.31M | $2.06B | (m) | (m) | 0.05% | (m) | (m) |
| 2024-09-30 | (m) | $293.96B | $148.00M | $2.18B | (m) | (m) | 0.05% | (m) | (m) |
| 2024-06-30 | (m) | $283.83B | $138.34M | $2.53B | (m) | (m) | 0.05% | (m) | (m) |
| 2024-03-31 | (m) | $276.54B | $136.72M | $2.52B | (m) | (m) | 0.05% | (m) | (m) |
| 2023-12-31 | (m) | $271.58B | $132.07M | $2.53B | (m) | (m) | 0.05% | (m) | (m) |
| 2023-09-30 | (m) | $262.17B | $124.62M | $2.34B | (m) | (m) | 0.05% | (m) | (m) |
| 2023-06-30 | (m) | $254.43B | $116.14M | $2.32B | (m) | (m) | 0.05% | (m) | (m) |
| 2023-03-31 | (m) | $247.54B | $109.97M | $2.14B | (m) | (m) | 0.04% | (m) | (m) |
| 2022-12-31 | (m) | $241.81B | $106.11M | $2.36B | (m) | (m) | 0.04% | (m) | (m) |
| 2022-09-30 | (m) | $238.59B | $93.40M | $2.37B | (m) | (m) | 0.04% | (m) | (m) |
| 2022-06-30 | (m) | $236.33B | $95.09M | $2.47B | (m) | (m) | 0.04% | (m) | (m) |
| 2022-03-31 | (m) | $229.67B | $95.05M | $2.61B | (m) | (m) | 0.04% | (m) | (m) |
| 2021-12-31 | (m) | $221.10B | $94.20M | $2.45B | (m) | (m) | 0.04% | (m) | (m) |
| 2021-09-30 | (m) | $213.99B | $99.59M | $2.35B | (m) | (m) | 0.05% | (m) | (m) |
| 2021-06-30 | (m) | $204.32B | $98.30M | $-4.32B | (m) | (m) | 0.05% | (m) | (m) |
| 2021-03-31 | (m) | $196.28B | $95.76M | $-4.54B | (m) | (m) | 0.05% | (m) | (m) |
| 2020-12-31 | (m) | $194.55B | $91.35M | $-4.85B | (m) | (m) | 0.05% | (m) | (m) |
| 2020-09-30 | (m) | $189.89B | $74.41M | $-5.14B | (m) | (m) | 0.04% | (m) | (m) |
| 2020-06-30 | (m) | $186.29B | $68.02M | $1.16B | (m) | (m) | 0.04% | (m) | (m) |
| 2020-03-31 | (m) | $186.16B | $66.77M | $1.16B | (m) | (m) | 0.04% | (m) | (m) |
| 2019-12-31 | (m) | $182.06B | $58.48M | $897.54M | (m) | (m) | 0.03% | (m) | (m) |
| 2019-09-30 | (m) | $179.59B | $58.87M | $1.11B | (m) | (m) | 0.03% | (m) | (m) |
| 2019-06-30 | (m) | $177.25B | $57.14M | $1.09B | (m) | (m) | 0.03% | (m) | (m) |
| 2019-03-31 | (m) | $175.15B | $55.98M | $1.07B | (m) | (m) | 0.03% | (m) | (m) |
| 2018-12-31 | (m) | $172.87B | $61.48M | $1.50B | (m) | (m) | 0.04% | (m) | (m) |
| 2018-09-30 | (m) | $167.94B | $62.32M | $1.44B | (m) | (m) | 0.04% | (m) | (m) |
| 2018-06-30 | (m) | $163.76B | $64.22M | $1.15B | (m) | (m) | 0.04% | (m) | (m) |
| 2018-03-31 | (m) | $159.33B | $65.16M | $935.77M | (m) | (m) | 0.04% | (m) | (m) |
| 2017-12-31 | (m) | $155.44B | $65.62M | $1.08B | (m) | (m) | 0.04% | (m) | (m) |
| 2017-09-30 | (m) | $153.14B | $62.21M | $1.06B | (m) | (m) | 0.04% | (m) | (m) |
| 2017-06-30 | (m) | $151.58B | $60.02M | $1.42B | (m) | (m) | 0.04% | (m) | (m) |
| 2017-03-31 | (m) | $149.76B | $66.45M | $1.78B | (m) | (m) | 0.04% | (m) | (m) |
| 2016-12-31 | (m) | $148.31B | $71.93M | $2.10B | (m) | (m) | 0.05% | (m) | (m) |
| 2016-09-30 | (m) | $146.85B | $64.99M | $1.53B | (m) | (m) | 0.04% | (m) | (m) |
| 2016-06-30 | (m) | $144.76B | $71.01M | $1.83B | (m) | (m) | 0.05% | (m) | (m) |
| 2016-03-31 | (m) | $142.11B | $67.32M | $1.64B | (m) | (m) | 0.05% | (m) | (m) |
| 2015-12-31 | (m) | $139.08B | $63.63M | $325.94M | (m) | (m) | 0.05% | (m) | (m) |
| 2015-09-30 | (m) | $135.96B | $60.94M | $417.37M | (m) | (m) | 0.04% | (m) | (m) |
| 2015-06-30 | (m) | $132.08B | $57.44M | $87.18M | (m) | (m) | 0.04% | (m) | (m) |
| 2015-03-31 | (m) | $128.19B | $54.50M | $-134.51M | (m) | (m) | 0.04% | (m) | (m) |
| 2014-12-31 | (m) | $123.98B | $51.45M | $530.87M | (m) | (m) | 0.04% | (m) | (m) |
| 2014-09-30 | (m) | $119.57B | $43.11M | $778.88M | (m) | (m) | 0.04% | (m) | (m) |
| 2014-06-30 | (m) | $112.45B | $41.54M | $685.81M | (m) | (m) | 0.04% | (m) | (m) |
| 2014-03-31 | (m) | $104.01B | $39.79M | $709.58M | (m) | (m) | 0.04% | (m) | (m) |
| 2013-12-31 | (m) | $96.08B | $38.17M | $758.58M | (m) | (m) | 0.04% | (m) | (m) |
| 2013-09-30 | (m) | $87.96B | $36.27M | $898.40M | (m) | (m) | 0.04% | (m) | (m) |
| 2013-06-30 | (m) | $82.55B | $34.42M | $1.10B | (m) | (m) | 0.04% | (m) | (m) |
| 2013-03-31 | (m) | $81.38B | $32.25M | $1.24B | (m) | (m) | 0.04% | (m) | (m) |
| 2012-12-31 | (m) | $80.64B | $29.27M | $1.26B | (m) | (m) | 0.04% | (m) | (m) |
| 2012-09-30 | (m) | $79.49B | $26.12M | $1.25B | (m) | (m) | 0.03% | (m) | (m) |
| 2012-06-30 | (m) | $80.61B | $25.70M | $1.21B | (m) | (m) | 0.03% | (m) | (m) |
| 2012-03-31 | (m) | $81.00B | $28.93M | $1.21B | (m) | (m) | 0.04% | (m) | (m) |
| 2011-12-31 | (m) | $80.69B | $27.98M | $1.21B | (m) | (m) | 0.03% | (m) | (m) |
| 2011-09-30 | (m) | $80.22B | $28.36M | $1.20B | (m) | (m) | 0.04% | (m) | (m) |
| 2011-06-30 | (m) | $79.53B | $28.33M | $1.21B | (m) | (m) | 0.04% | (m) | (m) |
| 2011-03-31 | (m) | $78.97B | $26.18M | $1.17B | (m) | (m) | 0.03% | (m) | (m) |
| 2010-12-31 | (m) | $78.51B | $30.45M | $1.12B | (m) | (m) | 0.04% | (m) | (m) |
| 2010-09-30 | (m) | $77.95B | $30.84M | $1.10B | (m) | (m) | 0.04% | (m) | (m) |
| 2010-06-30 | (m) | $76.95B | $30.87M | $1.08B | (m) | (m) | 0.04% | (m) | (m) |
| 2010-03-31 | (m) | $75.75B | $29.33M | $1.01B | (m) | (m) | 0.04% | (m) | (m) |
| 2009-12-31 | (m) | $73.76B | $26.94M | $948.25M | (m) | (m) | 0.04% | (m) | (m) |
| 2009-09-30 | (m) | $71.76B | $27.14M | $883.75M | (m) | (m) | 0.04% | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-09-30 | (m) | $70.19B | $25.50M | $827.86M | (m) | (m) | 0.04% | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-09-30 | (m) | $65.67B | $24.06M | $788.74M | (m) | (m) | 0.04% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CARDINAL HEALTH INC (CAH) | United States | $51.753B | 29.38 |
| MCKESSON CORP (MCK) | United States | $101.317B | 19.78 |
| HERBALIFE LTD. (HLF) | $1.281B | 8.39 | |
| NU SKIN ENTERPRISES, INC. (NUS) | United States | $0.225B | -1.18 |
| Cosmos Health Inc. (COSM) | Greece | $0.038B | -0.60 |
| HWH International Inc. (HWH) | United States | $0.021B | -4.08 |
| DataMeds AI, Inc. (MEDS) | United States | $0.011B |